February 13, 2018 – Fort Detrick, MD
Priority Review Designation Received for Tafenoquine
February 7, 2018 – Washington DC
60P received Priority Review Designation from the USFDA for Tafenoquine (TQ) for prevention of malaria in adults
January 16, 2018
US Army Medical Research Lab Gets Fast Track Approval from USFDA for Malaria Drug
January 4, 2018
60 Degrees Pharmaceuticals Fast Tracked For Malaria Drug
December 18, 2017
60P Submits New Drug Application to USFDA for Antimalarial Drug Tafenoquine
May 16, 2017
60P’s investigational antimalarial agent tafenoquine is shown to be free of neurologic toxicity in adult rats according to recent study findings.
December 11, 2015
60P has received the first tranche of $4 million in a debt financing deal with Knight Therapeutics Inc. in support of our drug development program for tropical diseases.
August 31, 2015
60P has received approval to conduct a clinical study with celgosivir and modipafant in dengue patients in collaboration with Singapore General Hospital.
April 28, 2015
60P recently entered into a cooperative research and development agreement with the US Army to commercialize 60P003 (Tafenoquine) for malaria prophylaxis.
July 30, 2014
60P recently entered into an exclusive licensing deal with SingHealth and Duke-National University of Singapore Graduate Medical School to further develop celgosivir (60P001) for dengue fever.
June 11, 2014
One of 60P’s partners, Duke-NUS Medical School and its collaborators, completed a Phase I clinical study that demonstrated the safety of celgosivir in dengue patients and a trend toward faster NS1 clearance, suggesting the possibility of mitigating vascular permeability syndrome using glucosidase inhibitors.
April 1, 2014
60P has entered into a research collaboration agreement with the Duke-NUS Medical School to investigate the utility of different combinations of dengue drugs. Dengue, like other viral diseases, will likely require a combination of different host and virus-targeted molecules to achieve useful clinical benefit. Studies performed by Dr. Subhash Vasudevan.
January 1, 2014
60P established a subsidiary, 60P Australia, Pty. Ltd. 60P Australia will take the lead in continuing the company’s development of dengue therapeutics.
April 9, 2013
Report suggests that the incidence of dengue may have been underestimated by a factor of three. Therefore, prior estimates, including our own, of economic burden and the potential market for dengue drugs, will need to be revised upward.
September 8, 2012
60P estimates the potential market for dengue drugs to be $338 million annually. Published in Antiviral Research, the study was based on publicly available information regarding medical costs and lost productivity associated with clinical cases of dengue that result in an estimated economic burden of at least $1.7 billion a year.